Board Meeting Outcome for Approval of Unaudited (Standalone & Consolidated) Financial Results of The Company For the period ended on December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved unaudited financial results for Q3 FY26 and 9M FY26 along with a clean limited review report from M/s RP Khandelwal & Associates. On a standalone basis, revenue from operations for 9M FY26 jumped sharply to Rs 3,204.81 lakhs from Rs 1,347.76 lakhs in 9M FY25 (over 2.3x growth), while Q3 revenue was nearly flat at Rs 782.98 lakhs vs Rs 784.80 lakhs. Standalone PAT for 9M grew to Rs 99.32 lakhs (Rs 81.92 lakhs prior), but Q3 PAT dipped marginally to Rs 28.39 lakhs (Rs 29.40 lakhs). EPS stood at Rs 0.91 for 9M (Rs 0.82 prior). Consolidated 9M PAT was Rs 315.79 lakhs (Rs 300.77 lakhs prior) after including share of profit from associate Agribiotech Industries (29.76% stake). The company also acquired 99.10% of Solkit Distillery and Brewery Pvt Ltd in Sept 2025, though its operations have not yet commenced. A pending merger with Agribiotech Industries awaits regulatory approvals.
Strong revenue expansion is a positive signal of business scaling, but profit margins have compressed sharply as revenue growth has come with proportionally higher purchase costs, which investors should monitor. The pending merger and new subsidiary could reshape the business profile in coming quarters.